Turnstone Biologics Corp. (TSBX)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Oci, debt securities, available-for-sale, gain (loss), before adjustment, after tax, total | - | 30 | ||
| Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest | - | -17,002 | ||
| Benefit for income taxes | - | -816 | ||
| Research and development expense, total | - | 14,424 | ||
| General and administrative expense, total | - | 3,944 | ||
| Operating expenses | - | 18,368 | ||
| Operating income (loss) | - | -18,368 | ||
| Other income, net | - | 520 | ||
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | -17,848 | ||
| Other segment expense | 218 | - | ||
| Research and development-TIDAL-01 | -48 | - | ||
| Research and development-Compensation | 406 | - | ||
| Other income, net | 81 | - | ||
| Provision for income taxes | 12 | - | ||
| General and administrative | 5,388 | - | ||
| Depreciation expense | 31 | - | ||
| Net loss | -5,490 | -17,002 | ||
| Earnings per share, basic | -0.24 | -0.74 | ||
| Earnings per share, diluted | -0.24 | -0.74 | ||
| Weighted-average number of basic shares used in computing net earnings (loss) per share | 23,140,510 | 23,037,714 | ||
| Weighted-average number of diluted shares used in computing net earnings (loss) per share | 23,140,510 | 23,037,714 | ||